ICL and Agrematch to Develop Novel Crop Nutrition Solutions via AI

ICL and Agrematch to Develop Novel Crop Nutrition Solutions via AI

Global specialty minerals company and agriTech AI start-up to accelerate development of plant nutrition biostimulants 

Tel Aviv, Israel; September 7, 2023ICL Group (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced its agriFood innovation and investment platform, ICL Planet Startup Hub, has led an investment round in Agrematch, an artificial intelligence (AI) agriTech startup. The two companies agreed to launch a joint, multiyear program to use Agrematch’s AI system for the discovery of novel crop nutrition solutions, to bring innovative products to ICL’s global offerings.

Founded in 2017, by experienced entrepreneurs and industry veterans, Agrematch has been developing and refining its unique AI4AI – Artificial Intelligence for Active Ingredients platform ever since. ICL Growing Solutions, the agriculture division of ICL, is partnering with Agrematch as a strategic investment designed to be complementary to, and synergistic with, its long-term growth plans. The Agrematch platform is expected to produce proprietary compounds developed as unique biostimulants and plant nutrition products, ultimately optimizing overall plant and soil health and maximizing plant yield, quality and resilience. 

In recent years, AI has emerged as a key technology in discovering and developing innovative compounds, most frequently in drug discovery. According to an April 2022 study by Insider Intelligence, pharmaceutical companies have been saving nearly 70% of their discovery costs by using AI1. This new method has the potential to eliminate up to five years of the average seven-year time frame for bringing a candidate compound to trial2.

“ICL’s partnership with Agrematch brings the rapidly evolving application of AI into ICL’s agricultural development ecosystem,” noted Hadar Sutovsky, vice president of External Innovation and general manager of ICL Planet Startup Hub. “Agrematch’s AI4AI prediction platform has the potential to streamline our compound discovery process, reduce the time and costs involved, and lead to the development of more effective and efficient crop solutions.”

Mission Critical

Despite the urgent need for new sustainable crop nutrition products, the current discovery process is unable to meet demand. The prohibitively risky, costly and lengthy product development cycle – coupled with increasing regulatory requirements calling for sustainable products with a lower environmental footprint – has led to a reduction in the number of new product introductions. A faster and more efficient methodology, to identify new active ingredients for use in the development of ag products, is vital.

“We are excited to partner with ICL and explore new solutions for plant nutrition,” said Eyal Ben-Chanoch, CEO of Agrematch. “Using data science, and especially AI, has helped us to dramatically alter the discovery process, by eliminating both its sequential nature and the barriers that make the classical high-throughput screening methods costly, risky and time consuming. Our AI4AI platform was designed and built to discover new functional compounds that meet defined specifications.”

AI-based solution

Within the AI4AI system, Agrematch models are trained to fulfill the specifications of a well-defined product concept. The system’s predictive algorithms run through billions of molecules in a massive proprietary database. Novel compounds can thus be designed, creating a shortlist of candidates with the desired functionalities.

“This collaboration will focus on developing novel biostimulants products that provide superior results for plants,” said Elinor Erez, PhD, vice president of R&D for ICL Growing Solutions. “It supports our strategy to continue investing in the ag-biologicals market, which we see as highly complementary to – and aligning with – our existing agriculture business and the future of our specialty crop nutrition portfolios. ICL brings a huge contribution to this strategic collaboration, as this promising start-up will enjoy access to the global crop nutrition market, regulatory insights, agronomical aspects, and development, along with best-in-class group of R&D scientists and agronomists. Following an extensive evaluation of Agrematch’s technological capabilities, we are excited to collaborate with them to deliver novel ag-biological products to the global market.”


About ICL

ICL Group is a leading global specialty minerals company, which creates impactful solutions for humanity’s sustainability challenges in the food, agriculture and industrial markets.  ICL leverages its unique bromine, potash and phosphate resources, its global professional workforce, and its sustainability focused R&D and technological innovation capabilities, to drive the company’s growth across its end markets.  ICL shares are dual listed on the New York Stock Exchange and the Tel Aviv Stock Exchange (NYSE and TASE: ICL).  The company employs more than 12,500 people worldwide, and its 2022 revenues totaled approximately $10 billion. 

For more information, visit ICL’s website at icl-group.com.

To access ICL’s interactive CSR report, visit icl-group-sustainability.com.

You can also learn more about ICL on Facebook, LinkedIn, YouTube, Twitter and Instagram

About Agrematch

Agrematch is a pioneering data-science product discovery and development company providing novel bioactive compounds to industries that require new and improved products.  It’s unique artificial intelligence (AI) computational system has been designed, built, and demonstrated the rational identification of molecules with the desired compound-organism interaction. Focusing on agriculture at first yield strong platforms for herbicidal products – one with novel safe synthetics and one exclusively consist of naturals. Led by an outstanding multi-disciplinary team of industry veterans, Agrematch imagined and implemented this unique compound-based AI system that utilizes data science concepts, biology, chemistry, and industry know-how to accelerate the time to market, and reduce the total R&D costs and risks involved in bringing sustainable and durable products to market.  

For more information, please visit Agrematch’s website at www.agrematch.com 

1 https://www.insiderintelligence.com/insights/ai-machine-learning-in-drug-discovery-development/

2 https://www.scientificamerican.com/article/hunting-for-new-drugs-with-ai/

Forward Looking Statements

This announcement contains statements that constitute forward-looking statements, many of which can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others.

Forward-looking statements appear in this press release and include, but are not limited to, statements regarding the company’s intent, belief or current expectations.  Forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management.  Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: estimates, forecasts and statements as to management’s expectations with respect to, among other things, business and financial prospects, financial multiples and accretion estimates, future trends, plans, strategies, positioning, objectives and expectations, general economic, market and business conditions, supply chain and logistics disruptions, energy storage and electric vehicle growth, the potential for new COVID-19 variants, global unrest and conflict, governmental and regulatory requirements and actions by governmental authorities, including changes in government policy, changes in environmental, tax and other laws or regulations and the interpretation thereof.  As a result of the foregoing, readers should not place undue reliance on the forward‐looking statements contained in this press release concerning the timing of the transaction, or other more specific risks and uncertainties facing ICL, such as those set forth in the “Risk Factors” section of its Annual Report on Form 20-F filed on February 23, 2022, as such risk factors may be updated from time to time in its Current Reports on Form 6-K and other filings ICL makes with the U.S. Securities and Exchange Commission from time to time.

Forward-looking statements refer only to the date they are made, and the company does not undertake any obligation to update them in light of new information or future developments or to publicly release any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

Investor and Press Contact – Global

Peggy Reilly Tharp

VP, Global Investor Relations


[email protected]

Investor and Press Contact – Israel

Adi Bajayo

ICL Spokesperson


[email protected]